HuMax-CD20, a novel fully human anti-CD20 monoclonal antibody: Results of a phase I/II trial in relapsed or refractory follicular non-Hodgkins's lymphoma.

A Hagenbeek; T Plesner; P Johnson; L Pedersen; J Walewski; A Hellmann; B Link; T Robak; M Wojtukiewicz; M Pfreundschuh; M Kneba; A Engert; P Sonneveld; J Petersen; J Radford

HuMax-CD20, a novel fully human anti-CD20 monoclonal antibody: Results of a phase I/II trial in relapsed or refractory follicular non-Hodgkins's lymphoma.

A Hagenbeek, T Plesner, P Johnson, L Pedersen, J Walewski, A Hellmann, B Link, T Robak, M Wojtukiewicz, M Pfreundschuh, M Kneba, A Engert, P Sonneveld, J Petersen, J Radford

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	Undefined
Pages (from-to)	270B-270B
Number of pages	1
Journal	Blood
Volume	106
Issue number	11
Publication status	Published - 2005

Research Beacons, Institutes and Platforms

Photon Science Institute

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Hagenbeek, A., Plesner, T., Johnson, P., Pedersen, L., Walewski, J., Hellmann, A., Link, B., Robak, T., Wojtukiewicz, M., Pfreundschuh, M., Kneba, M., Engert, A., Sonneveld, P., Petersen, J., & Radford, J. (2005). HuMax-CD20, a novel fully human anti-CD20 monoclonal antibody: Results of a phase I/II trial in relapsed or refractory follicular non-Hodgkins's lymphoma. Blood, 106(11), 270B-270B.

@article{444700933d314cb39963507afa5dd712,

title = "HuMax-CD20, a novel fully human anti-CD20 monoclonal antibody: Results of a phase I/II trial in relapsed or refractory follicular non-Hodgkins's lymphoma.",

author = "A Hagenbeek and T Plesner and P Johnson and L Pedersen and J Walewski and A Hellmann and B Link and T Robak and M Wojtukiewicz and M Pfreundschuh and M Kneba and A Engert and P Sonneveld and J Petersen and J Radford",

year = "2005",

language = "Undefined",

volume = "106",

pages = "270B--270B",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier BV",

number = "11",

}

Hagenbeek, A, Plesner, T, Johnson, P, Pedersen, L, Walewski, J, Hellmann, A, Link, B, Robak, T, Wojtukiewicz, M, Pfreundschuh, M, Kneba, M, Engert, A, Sonneveld, P, Petersen, J & Radford, J 2005, 'HuMax-CD20, a novel fully human anti-CD20 monoclonal antibody: Results of a phase I/II trial in relapsed or refractory follicular non-Hodgkins's lymphoma.', Blood, vol. 106, no. 11, pp. 270B-270B.

TY - JOUR

T1 - HuMax-CD20, a novel fully human anti-CD20 monoclonal antibody: Results of a phase I/II trial in relapsed or refractory follicular non-Hodgkins's lymphoma.

AU - Hagenbeek, A

AU - Plesner, T

AU - Johnson, P

AU - Pedersen, L

AU - Walewski, J

AU - Hellmann, A

AU - Link, B

AU - Robak, T

AU - Wojtukiewicz, M

AU - Pfreundschuh, M

AU - Kneba, M

AU - Engert, A

AU - Sonneveld, P

AU - Petersen, J

AU - Radford, J

PY - 2005

Y1 - 2005

UR - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000233426101462&KeyUID=WOS:000233426101462

M3 - Meeting Abstract

SN - 0006-4971

VL - 106

SP - 270B-270B

JO - Blood

JF - Blood

IS - 11

ER -

HuMax-CD20, a novel fully human anti-CD20 monoclonal antibody: Results of a phase I/II trial in relapsed or refractory follicular non-Hodgkins's lymphoma.

Research Beacons, Institutes and Platforms

UN SDGs

Other files and links

Cite this